Search Drug Information, Interactions, Images, Dosage & Side Effects

Roxadustat strides ahead as anaemia treatment in CKD 18 Jan 2021

Roxadustat appears a promising treatment for anaemia in patients with chronic kidney disease (CKD), regardless of whether they are undergoing dialysis, according to two analyses presented at ASH 2020.

Diabetes mellitus, lower myocardial perfusion worsen heart failure, death risk

18 Jan 2021

IBD: Where there’s smoke, there’s colorectal neoplasia

18 Jan 2021

Muscle loss contributes to higher mortality, cost in COPD

18 Jan 2021

Saliva as sensitive as but cheaper than nasopharyngeal swabs for COVID-19 testing

18 Jan 2021

Flat flexible vs stable supportive shoes: which is better at reducing knee OA symptoms?

18 Jan 2021

PPI use tied to less severe gum disease

18 Jan 2021

No limit to heart health benefits of exercise

18 Jan 2021

Higher dulaglutide doses improve response in T2D patients uncontrolled on metformin

18 Jan 2021

Oily fish, omega-3 supplements protect against type 2 diabetes

18 Jan 2021

Beta blockers improves survival in sepsis, septic shock with persistent tachycardia

17 Jan 2021

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer 14 Jan 2021;
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.

ALL treatment: Current settings, future goals

Roshini Claire Anthony, 08 Jan 2021

Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem

Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021

The missing millions: Closing gaps in hepatitis B and C treatment

Rachel Soon, 04 Jan 2021

Ozempic

Contents : Semaglutide

Indications/Uses : Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or CIs; in addition to other medicinal products.

Galvus Met

Contents : Per 50 mg/500 mg FC tab Vildagliptin 50 mg, metformin HCl 500 mg. Per 50 mg/850 mg FC tab Vildagliptin 50 mg, metformin HCl 850 mg. Per 50 mg/1,000 mg FC tab Vildagliptin 50 mg, metformin HCl 1,000 mg

Indications/Uses : Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin & metformin as separate tab. In triple combination therapy w/ sulphonylurea as an adjunct to diet & exercise in patients inadequately controlled w/ metformin & sulphonylurea. In triple combination therapy w/ insulin as an adjunct to diet & exercise to improve glycaemic control in adult patients when stable dose of insulin & metformin alone do not provide adequate glycaemic control. Initial therapy in patients w/ type 2 DM whose diabetes is inadequately controlled by diet & exercise alone.

Xofluza

Contents : Baloxavir marboxil

Indications/Uses : Acute uncomplicated influenza in patients ≥12 yr who have been symptomatic for no >48 hr.

Trezilent

Contents : Alpelisib

Indications/Uses : In combination w/ fulvestrant for postmenopausal women & men w/ hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen.

Vizimpro

Contents : Dacomitinib

Indications/Uses : 1st-line treatment of patients w/ metastatic non-small cell lung cancer (NSCLC) w/ epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.

Adacel

Contents : Per 0.5 mL Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, pertactin 3 mcg, fimbriae types 2 & 3 5 mcg

Indications/Uses : Active booster immunization for prevention of tetanus, diphtheria & pertussis (whooping cough) in persons ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis vaccine (DTaP) in childn 4-6 yr.

Cosyrel

Contents : Per 5 mg/5 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 5 mg. Per 5 mg/10 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 10 mg. Per 10 mg/10 mg FC tab Bisoprolol fumarate 10 mg, perindopril arginine 10 mg

Indications/Uses : Substitution treatment of HTN &/or stable CAD (patients w/ history of MI &/or revascularisation) in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level. 5 mg/5 mg: Stable chronic heart failure w/ reduced systolic left ventricular function in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level.

New Molecule

3 New

New Indication

5 New

New Brand

2 New

pill identifier

Shape

Form

Color 1

Color 2

Markings

Shape

Form

Color 1

Color 2

Search Drug Information, Images & Medical News | MIMS Malaysia

Ozempic

Galvus Met

Xofluza

Trezilent

Vizimpro

Adacel

Cosyrel